The development of hybridoma technology has greatly increased the specificity of antibodies as well as permitted increased production of specific antibodies. Creative Biolabs provides a full range of services based on our state-of-the-art hybridoma platform. Our services cover all the steps of custom monoclonal antibody production, from gene expression to antibody purification and labeling. The quantity of antibodies can be small size for research uses or large scale for diagnostic industry. We have extensive experience and advanced equipment to produce antibodies within only 70 days.
Monoclonal antibodies (mAbs) are made by identical immune cells, and the key feature of a monoclonal antibody is its unique specificity. It recognizes only one particular epitope on a given molecule. As the intrinsic of high specificity, mAbs is a good tool to detect or purify their specific binding targets, such as cell surface markers or cancer cell receptors. For instance, different monoclonal antibody can be used to bind different cell surface markers on the B cells and T cells, thus the subsets various leukemia types can be distinguished. Besides, combined with other advanced techniques available in Creative Biolabs, such as bispecific technique, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR), mAbs have extended application to assist the development of cancer therapeutic.
Fig.1 Generation of monoclonal antibodies.1
Hybridoma technology is capable of producing large-scale monoclonal antibodies. The production of hybridoma relies on the fusion of immunized lymphocytes from an experimental animal with immortal myeloma cells. Tumor cell enables hybrid indefinite growth, whereas the B lymphocyte confers the capability to synthesize a specific antibody. After stabilization by repeated cell cloning, hybridoma is a promise cell line to produce large quantities of identical monoclonal antibody for years.
Through the development of hybridoma platform, the production and utilization of monoclonal antibodies have become increasingly popular. Monoclonal antibodies have been applied in several areas, including the prevention, diagnosis, and treatment of disease. In addition to therapeutic usage, monoclonal antibodies also play an important tool in biochemistry, molecular biology, and medicine.
Traditional hybridoma plating methods need multiple rounds of limited dilutions, which result in some non-producing antibody, faster-growing hybridoma cell lines. Also, multiple rounds of limited dilutions is extremely labor-intensive and time-consuming, thus making it difficult to isolate a large number of hybridoma clones from each cell fusion.
Creative Biolabs has extensive experience in hybridoma production and application. We improve the production process to get hybridomas faster with higher quality. We have developed a hybridoma platform which can select hybridoma cell clones immediately after fusion. Through this platform, we make sure the hybridoma colonies are clonal from the very beginning and choose some clones to test the secretion of a specific antibody. By this way, more than 1,500 hybridoma clones can be single-cells cloned in ten 15 cm dishes after a single fusion.
Creative Biolabs is an expert in monoclonal antibody production and application. For more detailed information, please feel free to contact us or directly sent us an inquiry.
Reference
For Research Use Only.
